Silexion Therapeutics Corp
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
PART I - FINANCIAL INFORMATION Item 1. Financial Statements
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Explanatory Note
Reverse Share Split
On July 28, 2025, we effected a reverse share split of our authorized ordinary shares (both issued and outstanding, and unissued) at a ratio of 1-for-15, with a market effective date of July 29, 2025. Unless specifically provided otherwise herein, all historical share, per share and related option and warrant data during the three-month period ended March 31, 2025 (which is used for comparative purposes to the corresponding period of 2026) that is presented in this quarterly report has been retroactively adjusted to reflect the reduced number of shares and the increase in the share price which resulted from that reverse share split.
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2026
INTERIM FINANCIAL STATEMENTS
MARCH 31, 2026
(Unaudited)
TABLE OF CONTENTS
| Page | |
| CONSOLIDATED FINANCIAL STATEMENTS: | |
|---|---|
| Condensed Consolidated Balance Sheets (unaudited) | F - 3 - F - 4 |
| Condensed Consolidated Statements of Operations (unaudited) | F - 5 |
| Condensed Consolidated Statements of Changes in Shareholders’ Equity | F - 6 |
| Condensed Consolidated Statements of Cash Flows (unaudited) | F - 7 - F - 8 |
| Notes to Condensed Consolidated Financial Statements (unaudited) | F - 9 - F - 21 |
F - 2
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.